Masoumi-Moghaddam S, Amini A, Wei AQ (2015) Sprouty2protein in prediction of post-treatment ascites in epithelial ovariancancer treated with adjuvant carbotaxol chemotherapy[J]. Am J Cancer Res 5: 2498-507.Masoumi-Moghaddam S., Amini A., Wei A. Q., Robertson G. & Morris D. L. ...
Case. We report a case of a young woman with borderline ovarian carcinoma and invasive tumor implants who underwent surgical debulking with preservation of future fertility followed by carboplatinum, paclitaxel (Taxol), and subsequent high-dose chemotherapy with subsequent peripheral blood stem cell ...
This experience suggests that chemotherapy may be warranted in cats following enucleation of a globe that appears to be affected in isolation • The most common ocular tissue to be involved is the anterior uvea (iris and ciliary body). Uveal involvement may be nodular or diffuse. However, ...
Twitter Google Share on Facebook carboplatin (redirected fromCarboplatinum) Medical [¦kär·bō′plat·ən] (medicine) A platinum coordination compound and anticancer agent used for advanced gynecologic malignancies, especially ovarian tumors, and for head and neck cancers and lung cancers. ...
For both small cell and non-small cell lung cancer a number of new agents have been evaluated over the last 2 to 3 years and among those navelbine, topotecan, gemcitabine, and taxanes (taxol and taxotere) have yielded the most encouraging results. For mesothelioma the therapeutic results are ...
The standard chemotherapy for ovarian cancer is paclitaxel/carboplatin. Patients often exhibit myelosuppressive toxicity, and the treatment response varies considerably. In this study, we investigated the previously reported SNP s 1199G>A (rs2229109), 1236C>T (rs1128503), 2677G>T/A (rs2032582),...
Adjuvant chemotherapycarbotaxolhigh-grade serous ovarian adenocarcinomaovarian cancerovarian cancer brain metastasiswhole-brain radiotherapyOvarian carcinoma is a common malignancy with a grim prognosis and a high mortality rate. Here, we report a rare case of an Iranian woman with four episodes of ...
ChemotherapyNSCLCPharmacokineticsPhase IBackground: BIBF 1120 is an oral potent inhibitor of vascular endothelial growth factor receptor, fibroblast growth factor receptor and platelet-derived growth factor receptor, the three key receptor families involved in angiogenesis. This phase I, open-label dose-...
chemotherapyNSCLCpharmacokineticsphaseIBackground BIBF 1120 is an oral potent inhibitor of vascular endothelial growth factor receptor, fibroblast growth factor receptor and platelet-derived growth factor receptor, the three key receptor families involved in angiogenesis. This phase I, open-label dose-...